Global

Feb 28, 2017
Pharmaceutical Executive
A panel of biopharma executives responsible for the Latin America business discuss investment, market access, and reimbursement issues in this key regional growth market for the life sciences industry.
Feb 21, 2017
Pharmaceutical Executive
Outlining one country’s unique price-setting model for novel drugs—and the resulting pre-launch strategies for manufacturers.
Jan 31, 2017
As the healthcare landscape evolves, pharmaceutical companies are being driven to embrace new, unique partnerships to go beyond the pill, writes Weng Si Ho.
Dec 21, 2016
2016 has been the year of the unpredictable — and the uncertainties this has generated will multiply and dominate the agenda in Europe in 2017, writes Reflector.
Dec 18, 2016
Pharmaceutical Executive
In a continent marked by stark differences in governance, growth and market potential, the best bets must be pursued off script.
Dec 17, 2016
Pharmaceutical Executive
How a strong corporate board can help ignite success in these regions. By Christopher Burrows and Saule Serikova.
Dec 06, 2016
Leela Barham speaks to NICE International and Imperial College’s Institute of Global Health Innovation about joining forces under the International Decision Support Initiative.
Nov 29, 2016
The European Medicine Association is determined keep open all options on the future of drug approvals in advance of a crucial meeting in December, writes Reflector.
Nov 25, 2016
The UK's NICE, like the NHS it supports, is looking at how to make big savings. One option is to get more "commercial". Leela Barham takes a look.
Nov 05, 2016
Leela Barham looks at the 18 recommendations of England’s Accelerated Access Review (AAR), which proposes how to speed up adoption of the best innovation in the NHS.
native1_300x100
lorem ipsum